The company’s Repatha (evolocumab) was added to optimised statin therapy in a phase 3 trial, and resulted in statistically significant regression of atherosclerosis in patients with coronary ...

New Repatha® Data Provide Insight Into the Benefits of Lipid Lowering Therapy in People With Type 1 Diabetes Amgen to Host Investor Webcast on MariTide Data on June 23 at 4:30 p.m. CDT ...

IMPORTANT SAFETY INFORMATION Contraindication: Repatha® is contraindicated in patients with a history of a serious hypersensitivity reaction to evolocumab or any of the excipients in Repatha®.

Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study for MariTide (maridebart cafraglutide, formerly AMG 133) in patients living with obesity, with and without Type 2 ...

Repatha (evolocumab) will be sold in the UK at a cost of $6,780 per year, less than half the $14,100 Amgen is charging for the drug in the US, with the price in other EU markets typically below ...

Evolocumab (Repatha) was approved for children ages 10 and older with heterozygous and homozygous FH based on a trial showing a 38.3 percentage point greater reduction in LDL cholesterol over 24 ...

PCSK9 inhibitors -- alirocumab (Praluent), evolocumab (Repatha), and inclisiran (Leqvio) -- are injections that keep LDL receptors free to bind to LDL cholesterol and keep it out of the blood ...

Some people using these drugs get joint pain, nausea, or flu -like symptoms. Examples include evolocumab (Repatha) and alirocumab (Praluent).

Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 2.5% in after-hours trading as the company's profit outlook for 2025 fell short of ...